October 18, 2022 NeuroSense Therapeutics Provides CEO’s Q3 Update and Nasdaq Opening Bell Ceremony Remarks Video Read More
August 2, 2022 NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study Read More
June 30, 2022 NeuroSense Therapeutics Reports Positive Preliminary Results from Novel Alzheimer’s Biomarker Study Read More
June 27, 2022 NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study Read More
June 1, 2022 NeuroSense Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC Read More
March 21, 2022 NeuroSense Shares Surge Over 400% As FDA Clears Initiating PK Study Of PrimeC Read More
December 13, 2021 NeuroSense initiates subject dosing in pharmacokinetics study of ALS asset Read More
December 8, 2021 NeuroSense Therapeutics Announces Pricing of $12 Million Initial Public Offering Read More